 | Medical glossary. |
T T T( T, T- T0 T1 T2 T3 T4 T9 TA TB TC TD TE TF TG TH TI TJ TK TL TM TN TO TP TQ TR TS TT TU TV TW TX TY TZ
| selected terms: 1,046 | page 1 of 11 |
- 1
- [Maxillary right third molar ( HL7V3.0 )] (UMLS (HL7) C0227032) tooth 1 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 10
- [Maxillary left lateral incisor ( HL7V3.0 )] (UMLS (HL7) C0227045) tooth 10 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 11
- [Maxillary left canine ( HL7V3.0 )] (UMLS (HL7) C0227046) tooth 11 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 12
- [Maxillary left first premolar ( HL7V3.0 )] (UMLS (HL7) C0227047) tooth 12 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 13
- [Maxillary left second premolar ( HL7V3.0 )] (UMLS (HL7) C0227048) tooth 13 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 14
- [Maxillary left first molar ( HL7V3.0 )] (UMLS (HL7) C0227051) tooth 14 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 15
- [Maxillary left second molar ( HL7V3.0 )] (UMLS (HL7) C0227052) tooth 15 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 16
- [Maxillary left third molar ( HL7V3.0 )] (UMLS (HL7) C0227053) tooth 16 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 17
- [Mandibular left third molar ( HL7V3.0 )] (UMLS (HL7) C0227054) tooth 17 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 18
- [Mandibular left second molar ( HL7V3.0 )] (UMLS (HL7) C0227055) tooth 18 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 19
- [The first, permanent, six-year molar of the lower left arch as defined by the Universal tooth numbering system. ( NCI )] (UMLS (HL7) C0227056) tooth 19 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 2
- [Maxillary right second molar ( HL7V3.0 )] (UMLS (HL7) C0227033) tooth 2 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 2.7.1.112
- [Related to B cell activation, PTK72 is a tyrosine kinase that becomes tyrosine phosphorylated and activated soon after anti-Ig stimulation of B cells. It is found associated with the mIg receptor complex. Unlike the membrane-bound Src-family tyrosine kinases, PTK72 is primarily present as a soluble cytosolic protein. It is probably the product of the syk gene and is highly related to the ZAP-70 protein associated with T cell activation. ( NCI )] (UMLS (NCI) C0134982) =Amino Acid, Peptide, or Protein; Enzyme ;;
- 20
- [Mandibular left second premolar ( HL7V3.0 )] (UMLS (HL7) C0227059) tooth 20 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 21
- [Mandibular left first premolar ( HL7V3.0 )] (UMLS (HL7) C0227060) tooth 21 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 22
- [Mandibular left canine ( HL7V3.0 )] (UMLS (HL7) C0227061) tooth 22 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 23
- [Mandibular left lateral incisor ( HL7V3.0 )] (UMLS (HL7) C0227062) tooth 23 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 24
- [Mandibular left central incisor ( HL7V3.0 )] (UMLS (HL7) C0227064) tooth 24 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 25
- [Mandibular right central incisor ( HL7V3.0 )] (UMLS (HL7) C0227065) tooth 25 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 26
- [Mandibular right lateral incisor ( HL7V3.0 )] (UMLS (HL7) C0227067) tooth 26 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 27
- [Mandibular right canine ( HL7V3.0 )] (UMLS (HL7) C0227068) tooth 27 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 28
- [Mandibular right first premolar ( HL7V3.0 )] (UMLS (HL7) C0227069) tooth 28 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 29
- [Mandibular right second premolar ( HL7V3.0 )] (UMLS (HL7) C0227070) tooth 29 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 3
- [Maxillary right first molar ( HL7V3.0 )] (UMLS (HL7) C0227034) tooth 3 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 30
- [The first, permanent, six-year molar of the lower right arch as defined by the Universal tooth numbering system. ( NCI )] (UMLS (HL7) C0227073) tooth 30 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 31
- [Mandibular right second molar ( HL7V3.0 )] (UMLS (HL7) C0227074) tooth 31 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 32
- [Mandibular right third molar ( HL7V3.0 )] (UMLS (HL7) C0227075) tooth 32 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 4
- [Maxillary right second premolar ( HL7V3.0 )] (UMLS (HL7) C0227037) tooth 4 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 5
- [Maxillary right first premolar ( HL7V3.0 )] (UMLS (HL7) C0227038) tooth 5 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 6
- [Maxillary right canine ( HL7V3.0 )] (UMLS (HL7) C0227039) tooth 6 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 7
- [Maxillary right lateral incisor ( HL7V3.0 )] (UMLS (HL7) C0227040) tooth 7 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 8
- [Maxillary right central incisor ( HL7V3.0 )] (UMLS (HL7) C0227042) tooth 8 =Body Part, Organ, or Organ Component =Permanent dentition;;
- 9
- [Maxillary left central incisor ( HL7V3.0 )] (UMLS (HL7) C0227043) tooth 9 =Body Part, Organ, or Organ Component =Permanent dentition;;
- To
- (UMLS (NCI) C1883351) =Qualitative Concept ;;
- TO BE DELETED INGREDIENT PREPARATIONS
- (UMLS (NDFRT)) (C1377153) =Classification =Drug;; =Acriflavine;;ALUMINUM (AS HYDROXIDE);;AMBENONIUM;;AMODIAQUINE;;Benactyzine;;Betamethasone Acetate;;Betamethasone Benzoate;;bile salt;;Bioflavonoid;;BORIC;;CALCIUM (AS CALCIUM CARBONATE);;1,3-Bis(2-chloroethyl)-1-nitrosourea;;CEFMETAZOLE;;CEFONICID;;chlortetracycline;;(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol;;CHOLINE (AS BITARTRATE);;Chymopapain;;COLISTIN;;COPPER GLUCONATE;;deoxycorticosterone;;PHENYLPROPANOLAMINE HYDROCHLORIDE;;dinoprost;;1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl;;emetine;;E. coli;;ethopropazine;;ETHYLESTRENOL;;GALLAMINE;;CHORIOGONADOTROPIN;;hexobarbital;;ichthammol;;IFN alpha-2B;;LYPRESSIN;;MAGNESIA;;MAGNESIUM (AS SULFATE);;Merbromin;;METHACYCLINE;;Methandriol;;Methandrostenolone;;methantheline;;METHARBITAL;;METHOXAMINE;;NEOMYCIN (AS SULFATE);;3-Pyridinecarboxamide;;NICOTINYL ALCOHOL;;NOVOBIOCIN;;Nylidrin;;OXYPHENBUTAZONE;;Oxyphenonium;;HYDROXYAMPHETAMINE;;PARAMETHASONE;;PARGYLINE;;PENTYLENETETRAZOL;;1-Acetamido-4-ethoxybenzene;;PHENYLBUTAZONE;;PIPERACETAZINE;;PIPERAZINE;;CHLORIDE (AS POTASSIUM);;POVIDONE IODINE;;PPD;;SENNA;;FLUORIDE (AS SODIUM FLUORIDE);;alcalase novo;;SUPROFEN;;[VT101] CYANOCOBALAMIN;;[VT500] VITAMIN D;;2-phenylbenzimidazole-5-sulfonic acid;;Bentiromide;;.beta.-Carotene;;bone meal;;Bromfenac;;Calcium Polycarbophil;;(6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid;;chloroxylenol;;cresatin;;COOPER (AS CUPRIC OXIDE);;D-(+)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutyramide;;DIPHENYLPYRALINE;;ethaverine;;FERROUS FUMARATE;;FERROUS SULFATE;;(E)-4,4'-(1,2-ethenediyl)-bisphenol bis(dihydrogen phosphate);;hexocyclium;;Homatropine Methylbromide;;HYDRIODIC ACID;;HYDROXYPROPYL CELLULOSE;;HYDROXYPROPYL;;mercuric chloride, ammoniated;;mercuric oxide;;METHYL More…
- To be specified in another part of the message
- (UMLS (HL7) C1547974) =Intellectual Product =Specimen Source Codes;;
- To identify measures at a point in time. This is a synonym for "spot" or "random" as applied to urine measurements.
- (UMLS (HL7) C1547060) =Temporal Concept =Duration categories;;
- TO/NIAOU/THYME/ROSEM/EUC/P-NDL CREAM (GRAMS)
- [ ] (UMLS (RXNORM) C1346755) TURPENTINE OIL/NIAOULI OIL/THYME/ROSEM/EUCALYP/PINE NDL OIL CREAM (GRAMS);;TURPENTINE OIL/NIAOULI OIL/THYME/ROSEM/EUCALYP/PINE NDL OIL CREAM (GRAMS) =Clinical Drug
- toad
- [tailess amphibian with a dry, warty skin; chiefly terrestrial, entering water only during breeding season; most common genus is Bufo. ( CSP )] (UMLS (CSP) C0006358) =Amphibian ;; =Frog;;
- TOBACCO
- [toxic solanaceous American plant Nicotiana tabacum; contains nicotine and other biologically active chemicals; dried leaves are used for smoking, inhalation, or chewing.(CSP)] (UMLS (NDFRT)) (C0040329) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance =angiosperm;;consumer product;;Unclassified Ingredients;;Unclassified Ingredient Preparations =smokeless tobacco;;TOBACCO 1 UNT
- Tobacco - chewed
- (UMLS (HL7) C1547289) =Daily or Recreational Activity =Recreational Drug Use Code;;
- Tobacco - smoked
- (UMLS (HL7) C1547293) =Intellectual Product =Recreational Drug Use Code;;
- TOBACCO 1 UNT
- (UMLS (NDFRT)) (C1377154) =Clinical Drug =TOBACCO;; =ALLERGENIC EXTRACT INJ
- Tobacco abuse
- [tobacco used to the detriment of a person's health or social functioning; tobacco dependence is included.(CSP)] (UMLS (ICPC) C0040336) (Tobacco abuse; TABAKO ABUSUA; Tobakmisbrug; Tabaks misbruik; TUPAKKARIIPPUVUUS; Tabagisme; Nikotinabusus; (108); nikotin abusus; Abuso di tabacco; TOBAKKMISBRUK/-PROBLEM; Abuso de tabaco; Abuso del tabaco; TOBAKSBEROENDE) =Mental or Behavioral Dysfunction =Substance-Related Disorders; Symptoms and Complaints Component; PSYCHOLOGICAL; substance abuse related disorder =smokeless tobacco;
- tobacco abuse education
- [instruction or training that encourages behaviors most likely to optimize health potentials through information about tobacco abuse; facilitates the prevention of tobacco abuse, frequently for those who are at risk; also includes instruction or training that increases the awareness and favorably influences the attitudes and knowledge about tobacco abuse on a personal or community basis; it also includes the training of medical personnel about tobacco abuse for prevention or treatment programs, for this type of tobacco abuse education postcoordinate with the appropriate health professional education term; this concept may overlap with TOBACCO ABUSE PREVENTION. ( CSP )] (UMLS (CSP) C0597588) =Educational Activity =drug abuse education;;tobacco abuse prevention
- tobacco abuse prevention
- [increasing the awareness of tobacco abuse, prevention of tobacco abuse in susceptible individuals or populations through promotion of health or with chemopreventive methods, and prevention of complications or after-effects of existing disease; this concept may overlap with TOBACCO ABUSE EDUCATION. ( CSP )] (UMLS (CSP) C1171222) =Therapeutic or Preventive Procedure ;; =disease/disorder prevention/control;; =smoking cessation;;tobacco abuse education;;
- Tobacco Chewing Toxicity
- (UMLS (NCI) C1883352) =Injury or Poisoning ;;
- Tobacco Chewing-Related Carcinoma
- (UMLS (NCI) C1336759) =Neoplastic Process ;;
- Tobacco Consumption
- [Use of tobacco in any form i.e. smoking, chewing or sniffing. ( NCI )] (UMLS (NCI) C0543414) =Finding
- Tobacco Control Research
- (UMLS (NCI) C1519532) =Research Activity
- Tobacco Epidemiology
- [Population-based research studies that assess associations between tobacco use, behavioral and biological factors, and cancer. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519540) Tobacco Use Epidemiology;; =Research Activity
- tobacco mosaic virus
- [plant virus containing RNA which causes mosaic disease of tobacco. ( CSP )] (UMLS (CSP) C0040333) =Virus =plant virus;;RNA virus
- Tobacco Related Exposure
- (UMLS (NCI) C1710429) =Environmental Effect of Humans ;;
- Tobacco Research Implementation Group
- [Created to establish NCI's tobacco-related cancer research priorities for the next five to seven years. The first initiative of the group creates a collaborative Transdisciplinary Tobacco Research Centers program. The second program funds state and community tobacco control intervention research. ( NCI )] (UMLS (NCI) C1519533) TRIG;; =Professional or Occupational Group
- Tobacco Surveillance
- [Surveillance to improve the capacity to identify and understand emerging disparities in tobacco use, particularly among at risk youth. (from The NCI Strategic Plan to Reduce Health Disparities) ( NCI )] (UMLS (NCI) C1519534) =Research Activity
- Tobacco Toxicity
- (UMLS (NCI) C1883353) =Injury or Poisoning ;;
- Tobacco Use and Related Risk Factors, Surveillance
- [Research studies that assess trends in tobacco-related risk factors, behaviors and health services to determine changes over time and the influence of these trends on cancer incidence, morbidity, mortality and survival. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519543) =Research Activity
- Tobacco Use Basic Biological Research
- [Laboratory-based research studies that assess the effects of tobacco and tobacco products on cell biology and cellular mechanisms of action, including the role of tobacco and tobacco byproducts in the initiation and promotion of cancer and the biological. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519535) =Research Activity
- TOBACCO USE DIS-ANTEPART
- [ ] (UMLS (ICD9CM) C1719561) Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication =Disease or Syndrome
- TOBACCO USE DIS-DEL-P/P
- [ ] (UMLS (ICD9CM) C1719560) Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication =Disease or Syndrome
- TOBACCO USE DISOR-DELLIV
- [ ] (UMLS (ICD9CM) C1719559) Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition =Disease or Syndrome
- Tobacco use disorder complicating pregnancy, childbirth, or the puerperium
- [ ] (UMLS (ICD9CM) C1719563) =Disease or Syndrome
- Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication
- [ ] (UMLS (ICD9CM) C1719562) TOBACCO USE DIS-POSTPART =Disease or Syndrome
- Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care or not applicable
- [ ] (UMLS (ICD9CM) C1719558) TOBACCO USE DISORD-UNSP =Disease or Syndrome
- Tobacco Use Policy Research
- [Research studies that assess the effect of policies, including worksite, community, state and Federal policies, on tobacco initiation and use. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519541) =Research Activity
- Tobacco Use Prevention Research
- [Studies to develop and test interventions that are designed to prevent the initiation of tobacco use among individuals. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519542) =Research Activity
- Tobacco Use, Cessation Research
- [Studies to test and implement interventions among groups of individuals that are designed to stop current use of tobacco. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519536) =Research Activity
- Tobacco Use, Chemoprevention
- [Studies that assess the administration of specific and/or dietary modifications to reverse or suppress the carcinogenic effects of tobacco and prevent the development of invasive cancer. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519537) =Research Activity
- Tobacco Use, Combined Prevention/Cessation Research
- [Studies to test and implement interventions among groups of individuals that are designed to both prevent the initiation of tobacco use and stop current tobacco use. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519538) =Research Activity
- Tobacco Use, Community and State Intervention Research
- [Research studies that test group and population-based interventions and the dissemination of group and population-based interventions to prevent and reduce tobacco use. (NCI/TRIP) ( NCI )] (UMLS (NCI) C1519539) =Research Activity
- Tobacco-Associated Carcinogen
- [A chemical that is present in tobacco products, including pipe, cigarette and cigar as well as chewing tobacco and snuff, or that is produced during the burning of tobacco and causes a carcinogenic effect in humans. ( NCI )] (UMLS (NCI) C1519531) =Hazardous or Poisonous Substance
- Tobacco-Related Carcinoma
- (UMLS (NCI) C1336758) =Neoplastic Process ;;
- Tobagoan
- [Denotes the inhabitants of Tobago, a person from there, or their descendants elsewhere. ( NCI )] (UMLS (NCI) C1553339) =Population Group =African American;;
- Tobamovirus
- [A genus of plant viruses in which the virion is a rigid filament. Transmission is by mechanical inoculation or seed. The type species is TOBACCO MOSAIC VIRUS. ( MSH )] (UMLS (CSP) C0206375) =Virus
- TOBRA/NAPHAZOLINE HCL/DEXAMETH DROPS
- [ ] (UMLS (RXNORM) C1354098) TOBRAMYCIN/NAPHAZOLINE HCL/DEXAMETHASONE DROPS =Clinical Drug
- TOBRA/NITROFURAZONE/PHENYLEPH DROPS
- [ ] (UMLS (RXNORM) C1354231) TOBRAMYCIN/NITROFURAZONE/PHENYLEPHRINE DROPS =Clinical Drug
- Tobradex
- [ ] (UMLS (RXNORM) C0723765) =Steroid; Antibiotic ;;
- Tobraflex
- [ ] (UMLS (RXNORM) C1829317) =Pharmacologic Substance ;;
- Tobralcon
- [ ] (UMLS (RXNORM) C0723766) =Organic Chemical; Antibiotic ;;
- Tobralcon 3 MG/ML Ophthalmic Solution
- [ ] (UMLS (RXNORM) C0709258) =Clinical Drug
- Tobralex
- [ ] (UMLS (RXNORM) C0730710) =Organic Chemical; Antibiotic ;;
- Tobralex 3 MG/ML Ophthalmic Solution
- [ ] (UMLS (RXNORM) C0360897) =Clinical Drug
- TOBRAMYCIN
- [An aminoglycoside antibiotic derived from Streptomyces tenebrarius with bacteriostatic activity. Following active transport into the cell, tobramycin binds irreversibly to a specific aminoglycoside receptor on the bacterial 30S ribosomal subunit and interferes with the initiation complex between messenger RNA and the 30S subunit, thereby inhibiting initiation of protein synthesis, consequently leading to bacterial cell death. In addition, tobramycin induces misreading of the mRNA template causing incorrect amino acids to be incorporated into the growing polypeptide chain, consequently interfering with protein elongation. ( NCI )] (UMLS (NCI) C0040341) =Carbohydrate; Antibiotic ;; =[AM300] AMINOGLYCOSIDES;;Nebramycin;;[OP201] ANTIBACTERIALS, TOPICAL OPHTHALMIC;;[RE900] RESPIRATORY AGENTS, OTHER =TOBRAMYCIN SULFATE;;TOBRAMYCIN 300 MG/5ML;;TOBRAMYCIN 0.3 %;;
- Tobramycin 0.0003 MG/MG
- [ ] (UMLS (RXNORM) C1968129) =Clinical Drug
- Tobramycin 0.003 MG/MG
- [ ] (UMLS (RXNORM) C1123562) =Clinical Drug
- Tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex]
- [ ] (UMLS (RXNORM) C0709264) =Clinical Drug
- Tobramycin 0.003 MG/MG Topical Gel
- [ ] (UMLS (RXNORM) C1344942) TOBRAMYCIN SULFATE 0.3% GEL (GM);;TOBRAMYCIN SULFATE 0.3% GEL (GM);; =Clinical Drug
- Tobramycin 0.003 MG/MG [Tobrex]
- [ ] (UMLS (RXNORM) C1600998) =Clinical Drug
- TOBRAMYCIN 0.3 %
- (UMLS (NDFRT)) (C1379387) =Clinical Drug =TOBRAMYCIN;; =Dexamethasone 0.001 MG/MG / Tobramycin 0.003 MG/MG Ophthalmic Ointment;;DEXAMETHASONE 0.1 %WV / TOBRAMYCIN 0.3 %WV OPHTHALMIC SUSPENSION;;TOBRAMYCIN 0.3% OINTMENT(GM);;BENZALKONIUM CHLORIDE 0.0 %WW / TOBRAMYCIN 0.3 %WV / TOBRAMYCIN 0.3 %WW OPHTHALMIC SOLUTION [TOBRAMYCIN]
- TOBRAMYCIN 0.3 %WV / TOBRAMYCIN 3 MG OPHTHALMIC SOLUTION [TOBREX]
- [ ] (UMLS (RXNORM) C0709260) =Clinical Drug
- TOBRAMYCIN 0.3% OINTMENT(GM)
- [ ] (UMLS (RXNORM) C0980742) Tobramycin 0.003 MG/MG Ophthalmic Ointment;;TOBRAMYCIN 0.3 %WW OPHTHALMIC OINTMENT;;TOBRAMYCIN 0.3 %WW TOPICAL OINTMENT;;TOBRAMYCIN 0.3% OINT,OPH;;TOBRAMYCIN 0.3% OINTMENT(GM);;TOBRAMYCIN 0.3% Ophthalmic (non-systemic) ointment;;TOBRAMYCIN SULFATE 0.3% OINTMENT(GM);;TOBRAMYCIN SULFATE 0.3% OPHTHALMIC OINTMENT(GM);;TOBRAMYCIN SULFATE0.3%OPHTHALMICOINTMENT(GM);; =Clinical Drug =TOBRAMYCIN 0.3 %;;
- TOBRAMYCIN 0.3%-0.3% COMBINATION PACKAGE
- [ ] (UMLS (RXNORM) C1361552) =Drug Delivery Device
- Tobramycin 0.6 MG/ML
- [ ] (UMLS (RXNORM) C1125891) =Clinical Drug
- Tobramycin 0.6 MG/ML Injectable Solution
- [ ] (UMLS (RXNORM) C0982873) TOBRAMYCIN SO4 0.6MG/ML/NACL 0.9% INJ =Clinical Drug =SODIUM CHLORIDE 0.9 %;;TOBRAMYCIN SULFATE 0.6 MG/ML
- Tobramycin 0.8 MG/ML
- [ ] (UMLS (RXNORM) C1126176) =Clinical Drug
- tobramycin 1.2 gm injectable powder for injection
- [ ] (UMLS (RXNORM) C1621993) (TOBRAMYCIN 1200 MG INTRAVENOUS INJECTION, POWDER, FOR SOLUTION;;TOBRAMYCIN 40 MG INTRAMUSCULAR INJECTION, SOLUTION;;TOBRAMYCIN 40 MG INTRAVENOUS INJECTION, SOLUTION;;tobramycin 40 mg/ml injectable solution;;TOBRAMYCIN SO4 1.2GM/VIL INJ;;TOBRAMYCIN SO4 40MG/ML INJ;;TOBRAMYCIN SULFATE 1.2 GM Injection (systemic) powder for solution;;TOBRAMYCIN SULFATE 1.2 GM/30ML INTRAMUSCULAR INJECTION;;TOBRAMYCIN SULFATE 1.2 GM/30ML INTRAVENOUS INJECTION;;TOBRAMYCIN SULFATE 1.2 GM/VIAL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION;;TOBRAMYCIN SULFATE 1.2G INJECTION VIAL (SDV,MDV OR ADDITIVE) (EA);;TOBRAMYCIN SULFATE 1.2G VIAL (SDV,MDV OR ADDITIVE) (EA);;TOBRAMYCIN SULFATE 40 MG INTRAMUSCULAR INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 40 MG INTRAVENOUS INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 40 MG/ML Injection (systemic) solution;;TOBRAMYCIN More…
- Tobramycin 1.2 MG/ML
- [ ] (UMLS (RXNORM) C1126174) =Clinical Drug
- Tobramycin 1.6 MG/ML
- [ ] (UMLS (RXNORM) C1123593) =Clinical Drug
- Tobramycin 10 MG/ML
- [ ] (UMLS (RXNORM) C1123572) =Clinical Drug
- tobramycin 10 mg/ml injectable solution
- [ ] (UMLS (RXNORM) C0980746) TOBRAMYCIN SO4 10MG/ML INJ;;TOBRAMYCIN SULFATE 10MG/ML AMPUL (ML);;TOBRAMYCIN SULFATE 10MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE 10 MG INTRAMUSCULAR INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 10 MG INTRAVENOUS INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 10 MG/ML Injection (systemic) solution;;TOBRAMYCIN SULFATE 10 MG/ML INTRAMUSCULAR INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 10 MG/ML INTRAVENOUS INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 10 MG/ML INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE;;TOBRAMYCIN SULFATE 10MG/ML AMPUL (ML);;TOBRAMYCIN SULFATE 10MG/ML INJECTION VIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE 10MG/ML INTRAVEN. VIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE 10MG/ML INTRAVENOUS VIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE 10MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE 20 MG/2ML INTRAMUSCULAR INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 20 MG/2ML INTRAVENOUS INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 60MG/6ML INTRAVEN. VIAL WITH THREADED PORT (ML);;TOBRAMYCIN SULFATE 80 MG/8ML INTRAVENOUS INJECTION, SOLUTION;;TOBRAMYCIN SULFATE 80MG/8ML INTRAVEN. VIAL WITH THREADED PORT (ML);;Tobramycin Sulfate, 10 mg/ml injectable solution;;TOBRAMYCIN SULFATE10MG/MLINJECTIONVIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE10MG/MLINTRAVEN.VIAL (SDV,MDV OR ADDITIVE) (ML);;TOBRAMYCIN SULFATE60MG/6MLINTRAVEN.VIAL WITH THREADED PORT (ML);;TOBRAMYCIN SULFATE80MG/8MLINTRAVEN.VIAL WITH THREADED PORT (ML);;Tobramycin, 10 mg/ml injectable solution;; =Clinical Drug =TOBRAMYCIN SULFATE 10 MG/ML;;
| UMLS | MEDINDEX.AM |
 to main page | About • Catalog. Medical sites. • UMLS.Semantic Types. • Feedback |  top of page |